| Literature DB >> 33213011 |
Luis Pla1,2,3, Anna Aviñó3,4, Ramón Eritja3,4, Alba Ruiz-Gaitán5, Javier Pemán5, Vicente Friaza6, Enrique J Calderón6,7, Elena Aznar1,2,3,8, Ramón Martínez-Máñez1,2,3,8, Sara Santiago-Felipe1,2,3.
Abstract
Pneumocystis pneumonia (PcP) is a disease produced by the opportunistic infection of the fungus Pneumocystis jirovecii. As delayed or unsuitable treatments increase the risk of mortality, the development of rapid and accurate diagnostic tools for PcP are of great importance. Unfortunately, current standard methods present severe limitations and are far from adequate. In this work, a time-competitive, sensitive and selective biosensor based on DNA-gated nanomaterials for the identification of P. jirovecii is presented. The biosensor consists of a nanoporous anodic alumina (NAA) scaffold which pores are filled with a dye reporter and capped with specific DNA oligonucleotides. In the presence of P. jirovecii genomic DNA, the gated biosensor is open, and the cargo is delivered to the solution where it is monitored through fluorescence spectroscopy. The use of capping oligonucleotides able to form duplex or triplex with P. jirovecii DNA is studied. The final diagnostic tool shows a limit of detection (LOD) of 1 nM of target complementary DNA and does not require previous amplification steps. The method was applied to identify DNA from P. jirovecii in unmodified bronchoalveolar lavage, nasopharyngeal aspirates, and sputum samples in 60 min. This is a promising alternative method for the routinely diagnosis of Pneumocystis pneumonia.Entities:
Keywords: Pneumocystis jirovecii; biosensor; molecular gates; nanoporous anodic alumina; oligonucleotides
Year: 2020 PMID: 33213011 PMCID: PMC7712664 DOI: 10.3390/jof6040292
Source DB: PubMed Journal: J Fungi (Basel) ISSN: 2309-608X
Sequences of the used oligonucleotides.
| Oligonucleotide | Sequence (5′-3′) | |
|---|---|---|
|
| Duplex antiparallel | 5′-GAAAGGGAAACAGCCCAG-3′ |
|
| Clamp antiparallel | 5′-GACAAAGGGAAAG-TTTT-GAAAGGGAAACAGCCCAG-3′ |
|
| Control clamp antiparallel | 5′-AGAGCAGAAAGGA-TTTT-GAAAGGGAAACAGCCCAG-3′ |
|
| Target complementary | 5′-CTGGGCTGTTTCCCTTTC-3′ |
Figure 1Representation of the preparation and sensing process: (1) Loading and functionalization of the nanoporous anodic alumina (NAA) support; (2) Capping with the oligonucleotides O1, O2, or O3, to obtain solids S1, S2, and S3, respectively; (3) Release of the cargo in the presence of P. jirovecii genomic DNA by forming (A) duplex structures when using solids S1 or S3 or (B) triplex hybridization structures when using S2 and (4) Calcination prior to the reutilization of the scaffold.
Figure 2Representation of the preparation and sensing process: (a) Loading and functionalization of the NAA support; (b) Capping with the oligonucleotides.
Atomic elements ratio in the different prepared solids by energy dispersive X-ray spectroscopy (EDX) studies.
| C/Al | N/Al | P/Al | |
|---|---|---|---|
|
| 1.52 | 0.38 | - |
|
| 0.76 | 0.40 | 0.01 |
|
| 0.58 | 0.53 | 0.02 |
|
| 0.74 | 0.42 | 0.02 |
Figure 3Rhodamine B delivery from S2 (a) in the absence and (b) in the presence of 1 nM of complementary O4 target sequence in a solution of hybridization buffer (20 mM Tris-HCl, 37.5 mM MgCl2, pH 7.5).
Figure 4Release of rhodamine B from solid S2 (A) in the presence of different concentrations of O4 and (B) in the presence of 1 ng/µL of genomic DNA from Aspergillus spp., C. albicans, C. tropicalis, C. auris, S. pompe, T. deformans, P. jirovecii, and 100 µL of hybridization buffer as a negative control. Assays were performed at 60 min in hybridization buffer at pH 7.5.
Detection of P. jirovecii in clinical samples using the reference method (PCR) and S2 material. Each sample was analyzed by triplicate.
| Sample a | Biological Fluid | Reference Method (PCR) b | S2 c | |
|---|---|---|---|---|
| Ct | Result | Result | ||
| 1 | Sputum | 28 | Infected | + |
| 2 | Sputum | 27.5 | Infected | + |
| 3 | BAL | 36.6 | Infected | + |
| 4 | Sputum | 28.5 | Infected | + |
| 5 | BAL | 38.8 | Infected | + |
| 6 | BAL | 19 | Infected | + |
| 7 | Sputum | 26.8 | Infected | + |
| 8 | Sputum | 30.28 | Infected | + |
| 9 | Sputum | 35.3 | Infected | + |
| 10 | Sputum | 34.9 | Infected | + |
| 11 | BAL | > 40 | Non-Infected | - |
| 12 | Sputum | > 40 | Non-Infected | - |
| 13 | NPA | - | Non- Infected | - |
| 14 | NPA | - | Non- Infected | - |
| 15 | NPA | - | Non- Infected | - |
| 16 | NPA | 33.6 | Infected | + |
| 17 | NPA | 37.2 | Infected | + |
| 18 | NPA | 34.9 | Infected | + |
| 19 | NPA | 28.8 | Infected | + |
| 20 | NPA | - | Non- Infected | - |
| 21 | NPA | 33.4 | Infected | + |
| 22 | NPA | - | Non- Infected | - |
| 23 | NPA | - | Non- Infected | - |
| 24 | NPA | - | Non- Infected | - |
| 25 | NPA | - | Non- Infected | + |
| 26 | NPA | - | Non- Infected | + |
| 27 | NPA | - | Non- Infected | - |
| 28 | NPA | 34.9 | Infected | - |
| 29 | NPA | 39.4 | Infected | - |
| 30 | NPA | 34.4 | Infected | + |
| 31 | NPA | 34.6 | Infected | + |
| 32 | NPA | 33.4 | Infected | + |
| 33 | NPA | 35.5 | Infected | - |
a Samples 1 to 12 were from patients of Hospital Universitari i Politècnic La Fe and samples 13 to 33 were from newborn infant patients of Hospital Universitario Virgen del Rocío. b Samples were considered positives (+) when two different aliquots of each patient were positive by specific PCR for P. jirovecii. c Samples were considered positives (+) when the fluorescence signal at 585 nm (λexc = 555 nm) was higher than the average fluorescence of the negative controls plus three times the standard deviation.